Xarelto, Stivarga and Eylea drive Bayer Healthcare Q2
This article was originally published in Scrip
Executive Summary
Germany's Bayer Group saw net income grow by 74.8% to reach €841 million in the second quarter. The Healthcare division helped boost sales, thanks in part to better than expected sales of new products Xarelto, Eylea and Stivarga.